Sialylated Lewis x as a tumor-associated antigen in stomach cancer

Sialylated Lewis (S-Lex) has been studied histologically and serologically in stomach cancer by the CSLEX1 monoclonal antibody. S-Lex was expressed in 73.9% of 46 stomach cancer tissues, 29.4% of metaplastic parts adjacent to cancer, and none of six gastric ulcer tissues including metaplasia. Serolo...

Full description

Saved in:
Bibliographic Details
Published inGan no rinsho. Japan journal of cancer clinics Vol. 32; no. 14; p. 1833
Main Authors Hirota, M, Fukushima, K, Hiratani, K, Funatsu, S, Suyama, N, Yokoyama, A, Hayashida, M, Tomonaga, A, Nakamura, N, Makiyama, K
Format Journal Article
LanguageJapanese
Published Japan 01.11.1986
Subjects
Antibodies, Monoclonal - immunology
Antigens, Neoplasm - analysis
Ascitic Fluid - immunology
Gastric Mucosa - immunology
Humans
Immunoenzyme Techniques
Metaplasia - immunology
Stomach Neoplasms - immunology
Online AccessGet more information

Cover

More Information
Summary:Sialylated Lewis (S-Lex) has been studied histologically and serologically in stomach cancer by the CSLEX1 monoclonal antibody. S-Lex was expressed in 73.9% of 46 stomach cancer tissues, 29.4% of metaplastic parts adjacent to cancer, and none of six gastric ulcer tissues including metaplasia. Serologically positive percentages were as follows: 26.0% of 100 stomach cancers, 0.9% of 322 benign diseases, and 0.7% of 280 healthy donors in the sera, as well as 72.4% of 29 ascites of stomach cancers and 5.3% of 17 effusions of benign diseases. These findings demonstrate that S-Lex possesses a potential usefulness as a tumor marker in stomach cancer.
ISSN:0021-4949